ISIN:FR0011191287

Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study

Lundi, juin 7, 2021 - 8:01am

Subject to contractual and market conditions, the Investor committed to subscribe up to a maximum gross amount of 81 million in OCEANE.

Key Points: 
  • Subject to contractual and market conditions, the Investor committed to subscribe up to a maximum gross amount of 81 million in OCEANE.
  • "We are pleased to announce this financing that extends our cash runway to continue to fund and complete our pivotal Phase III study, the PREMIER trial, in CMT1A.
  • This program relieves our financing overhang and allows us to progress our business plan to value creation for patients and shareholders with enthusiasm.
  • In the context of the Financing, the outstanding convertible bonds issued by the Company on February 3, 2021 shall be redeemed in cash by the Company.

Pharnext Reports Financial Results for Year-End 2020

Mercredi, avril 28, 2021 - 1:08am

b'Dissemination of a French Regulatory News, transmitted by EQS Group.\nThe issuer is solely responsible for the content of this announcement.\n'

Key Points: 

b'Dissemination of a French Regulatory News, transmitted by EQS Group.\nThe issuer is solely responsible for the content of this announcement.\n'

Pharnext Reports Financial Results for Year-End 2020

Mercredi, avril 28, 2021 - 1:07am

PXT864 has generated encouraging Phase II results in Alzheimer's disease and will be advanced through partnerships.

Key Points: 
  • PXT864 has generated encouraging Phase II results in Alzheimer's disease and will be advanced through partnerships.
  • Pharnext has developed a new drug discovery paradigm based on big genomics data and artificial intelligence: PLEOTHERAPY(TM).
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Pharnext or not currently considered material by Pharnext.
  • The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Pharnext to be materially different from such forward-looking statements.

Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')

Mercredi, mars 31, 2021 - 8:01am

Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')

Key Points: 
  • Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • PXT3003 is the Company's lead program to treat Charcot-Marie-Tooth disease type 1A ('CMT1A'), an indication with currently no existing approved therapies.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the high dose tested in the prior Phase III trial ('PLEO-CMT').
  • PXT3003 has shown promising and consistent results across preclinical and clinical studies in Phase II and Phase III (PLEO-CMT).

Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors

Jeudi, février 4, 2021 - 9:02pm

"We are pleased to announce this capital raise which demonstrates the strong continued support of our existing shareholders", said David Horn Solomon, Chief Executive Officer.

Key Points: 
  • "We are pleased to announce this capital raise which demonstrates the strong continued support of our existing shareholders", said David Horn Solomon, Chief Executive Officer.
  • "This funding will extend our cash runway to advance PXT3003 into the pivotal phase III trial in Charcot-Marie-Tooth disease Type 1A".
  • New shares resulting from the conversion of Convertible Bonds will be fully fungible with existing ordinary shares and will enjoy the same rights.
  • Following completion of the Capital Raise, they will own 14.45% and 24.14% respectively of the share capital of the Company.